← Back to Search

Other

JZP150 for Post-Traumatic Stress Disorder

Phase 2
Waitlist Available
Research Sponsored by Jazz Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Many of those who suffer from PTSD use cannabis. If you use cannabis, are you willing to refrain from cannabis use during the duration of the study (approximately 18 weeks)?
Did you experience a traumatic event within the last 9 years?
Must not have
Is your PTSD due to war combat?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 12

Summary

This trial tests a pill called JZP150 on adults with PTSD to see if it can reduce their symptoms. JZP150 blocks an enzyme to help increase brain chemicals that improve mood and reduce stress.

Eligible Conditions
  • Post Traumatic Stress Disorder

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean Change from Baseline to Week 12 in Clinician Administered Posttraumatic Stress Disorder (PTSD) Scale (CAPS-5) Total Symptom Severity Score
Secondary study objectives
Mean Change from Baseline to Week 12 in Clinical Global Impression of Severity (CGI-S)
Mean Change from Baseline to Week 12 in Patient Global Impression of Severity (PGI-S)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: JZP150 4.0 mgExperimental Treatment1 Intervention
Participants who will be randomized to receive JZP150 4.0 mg orally once daily for up to 12 weeks.
Group II: JZP150 0.3 mgExperimental Treatment1 Intervention
Participants who will be randomized to receive JZP150 0.3 mg orally once daily for up to 12 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Participants who will be randomized to receive placebo orally once daily for up to 12 weeks.

Who is running the clinical trial?

Jazz PharmaceuticalsLead Sponsor
249 Previous Clinical Trials
34,574 Total Patients Enrolled

Media Library

JZP150 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05178316 — Phase 2
Post-Traumatic Stress Disorder Research Study Groups: Placebo, JZP150 0.3 mg, JZP150 4.0 mg
Post-Traumatic Stress Disorder Clinical Trial 2023: JZP150 Highlights & Side Effects. Trial Name: NCT05178316 — Phase 2
JZP150 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05178316 — Phase 2
Post-Traumatic Stress Disorder Patient Testimony for trial: Trial Name: NCT05178316 — Phase 2
~70 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top